Cargando…

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3

Nuclear localized HER family receptor tyrosine kinases (RTKs) have been observed in primary tumor specimens and cancer cell lines for nearly two decades. Inside the nucleus, HER family members (EGFR, HER2, and HER3) have been shown to function as co-transcriptional activators for various cancer-prom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brand, Toni M., Iida, Mari, Luthar, Neha, Wleklinski, Matthew J., Starr, Megan M., Wheeler, Deric L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738522/ https://www.ncbi.nlm.nih.gov/pubmed/23951180 http://dx.doi.org/10.1371/journal.pone.0071518

Ejemplares similares

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
por: Iida, Mari, et al.
Publicado: (2014)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
por: Iida, Mari, et al.
Publicado: (2012)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

Computational analyses of curcuminoid analogs against kinase domain of HER2
por: Yim-im, Wannarat, et al.
Publicado: (2014)

The C-Terminal Transactivation Domain of STAT1 Has a Gene-Specific Role in Transactivation and Cofactor Recruitment
por: Parrini, Matthias, et al.
Publicado: (2018)

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone
por: Williams, Christopher C., et al.
Publicado: (2004)

Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion
por: Aceto, Nicola, et al.
Publicado: (2012)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
por: Rexer, Brent N., et al.
Publicado: (2011)

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA
por: Godfrey, Jack D., et al.
Publicado: (2022)

The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy
por: Wang, Shizhen Emily
Publicado: (2011)

MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression
por: Khan, Sheema, et al.
Publicado: (2016)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
por: Kankia, Ibrahim H., et al.
Publicado: (2021)

Androgen receptor transcriptional activity is required for heregulin-1β–mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase
por: Jathal, Maitreyee K., et al.
Publicado: (2023)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
por: Miladinova, Daniela
Publicado: (2023)

A Novel C-Terminal Domain of RecJ is Critical for Interaction with HerA in Deinococcus radiodurans
por: Cheng, Kaiying, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ie2uhc1v3ptiip27u746dqauod